Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data

Ibrahim Tohidi-Esfahani, MBBS,FRACP,FRCPA, Andrew Warden, Elena Malunis, Peter Liburdi deNardis, Javier Haurat, Marita Black, Stephen Opat, MBBS (Hons), FRACP, FRCPA, Shirley D'Sa, MD FRCPath, Marie José Kersten, MD PhD, Ruth Spearing, MD, Maria Lia Palomba, Adam J Olszewski, MD, Carl Harrington, Clare Scott, MBBS PhDFRACP, Judith Trotman, FRACP

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-138945

Published: 2020

Journal Articles

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Peter Mollee, MBBS, MMSc, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Ruth Spearing, MD, Jay Hocking, MBBS, FRACP, FRCPA, Bradley Augustson, MBBS FRACP FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Elizabeth M. Moore, PhD, Zoe McQuilten, Erica M. Wood, MBBS, FRACP, FRCPA, Cameron Wellard

Blood (2019) 134 (Supplement_1): 269.

https://doi.org/10.1182/blood-2019-129431

Published: 2019

Journal Articles

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

Richard Dillon, MA, PhD MRCP, FRCPath, Robert K. Hills, MA, DPhil, MSc, Sylvie D Freeman, MBChB, DPhil, Nicola Potter, PhD, Adam Ivey, BSc, MSc, PhD, Jelena Jovanovic, PhD, Anju Kanda, MSc, Manohursingh Runglall, MSc, Nicola Foot, MSc, Laura Upton, Asim Khwaja, MD PhD, Jamie Cavenagh, MD PhD, Ruth Spearing, MD, Alan K. Burnett, MD, Nigel H. Russell, David Grimwade, PhD MRCP, MRCPath

Blood (2018) 132 (Supplement 1): 2739.

https://doi.org/10.1182/blood-2018-99-113662

Published: 2018

Journal Articles

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor ( ClinTrialGov 00342316 )

Mats Brune, MD PhD, Thomas L. Kiss, MD, Elisabeth Wallhult, RN, Harald Anderson, PhD, Robert Delage, MD, Jürgen Finke, MD, Josee Hebert, MD, Martin Höglund, MD PhD, Ain Kaare, MD, Vladimir Lazarevic, MD PhD, Malin Nicklasson, MSc, Kari Remes, MD PhD, David Ritchie, MBChB, PhD FRACP, FRCPA, Mitchell Sabloff, MD, Ruth Spearing, MD, Alexandros Spyridonidis, MD PhD, Jeffrey Szer, MBBS, Per Ljungman, MD PhD

Blood (2018) 132 (Supplement 1): 205.

https://doi.org/10.1182/blood-2018-99-110260

Published: 2018

Journal Articles

Whimsical (Waldenström's Macroglobulinemia Study Involving CArt-wheeL): Empowering Patients Internationally to Contribute Patient-Derived Data for Observational Research

Ibrahim Tohidi-Esfahani, B MD, Andrew Warden, Peter deNardis, Elena Malunis, Shirley D'Sa, MD FRCP, FRCPath, Marie Jose Kersten, MD PhD, Maria Lia Palomba, MD, Ruth Spearing, MD, Loic Ysebaert, MD PhD, Sheeba K. Thomas, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Clare Scott, MBBS PhDFRACP, Carl Harrington, Judith Trotman, FRACP

Blood (2017) 130 (Supplement 1): 1502.

https://doi.org/10.1182/blood.V130.Suppl_1.1502.1502

Published: 2017

Journal Articles

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.

Mats L. Brune, MD, Jacob M. Rowe, MD, Jeff Szer, MD, Donna E. Hogge, MD, John Catalano, MD, Elisabeth Wallhult, RN, Bo I. Nilsson, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Stephane Allard, MD, Edward A. Stadtmauer, MD, Kristoffer Hellstrand, MD

Blood (2007) 110 (11): 1846.

https://doi.org/10.1182/blood.V110.11.1846.1846

Published: 2007

Journal Articles

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Mats Brune, MD, Sylvie Castaigne, MD, John Catalano, MD, Kurt Gehlsen, PhD, Wolf-Karsten Hofmann, MD, Anthony Ho, MD, Donna Hogge, MD, Bo Nilsson, MD, Reuven Or, MD, Jacob Rowe, MD, Bengt Simonsson, MD, Ruth Spearing, MD, Edward Stadtmauer, MD, Jeff Szer, MD, Elisabeth Wallhult, RN, Kristoffer Hellstrand, MD

Blood (2004) 104 (11): 261.

https://doi.org/10.1182/blood.V104.11.261.261

Published: 2004

Journal Articles

Low Incidence of Acute Graft-VS.-Host Disease (GVHD) Using Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) after Matched Sibling Donor (MSD) Non-Myeloablative Stem-Cell Transplants (NST) Conditioned with Fludarabine (FLU) and Low-Dose Total Body Irradiation (TBI).

Yago Nieto, MD, Nigel Patton, MD, Timothy Hawkins, MD, Ruth Spearing, MD, Scott I. Bearman, MD, Rachel Rabinovitch, MD, Chan Zeng, PhD, Anna Baron, PhD, Peter A. McSweeney, MD

Blood (2004) 104 (11): 5065.

https://doi.org/10.1182/blood.V104.11.5065.5065

Published: 2004

NARROW

Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheeL): A Global Patient-Derived Data Registry Capturing Treatment, Quality of Life and COVID-19 Data

Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor ( ClinTrialGov 00342316 )

Whimsical (Waldenström's Macroglobulinemia Study Involving CArt-wheeL): Empowering Patients Internationally to Contribute Patient-Derived Data for Observational Research

Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.

Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.

Low Incidence of Acute Graft-VS.-Host Disease (GVHD) Using Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) after Matched Sibling Donor (MSD) Non-Myeloablative Stem-Cell Transplants (NST) Conditioned with Fludarabine (FLU) and Low-Dose Total Body Irradiation (TBI).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only